Roche immunotherapy drug shrinks tumors in early bladder cancer study

May 31, 2014 1:36 PM

6
0

ZURICH (Reuters) - Roche's experimental drug that spurs the immune system to fight cancer shrank tumors in 43 percent of people with a specific type of metastatic bladder cancer, according to results of an early-stage trial published on Saturday.

The drug MPDL3280A is part of a closely-watched class of treatments known as anti-PDL1 therapies, which work by blocking a tumor's ability to evade the immune system's defense.